Overview

Gender

male

Dr. Neil Campbell joined Marizyme as President & CEO in 2020. Neil J. Campbell is President and CEO, Helomics Corporation, a privately-held personalize healthcare oncology company, Additionally, Mr. Campbell also serves as Executive Chairman for Mosaigen® Corporation, a global technology development corporation; Board member for PA BIO, and as an industry advisor and operating partner for Healthcare Royalty Partners, a private equity healthcare firm in the U.S.



Mr. Campbell has more than 30 years of life science/healthcare/investment industry experience. Formerly, Mr. Campbell was President and CEO and Co-Founder of SuperNova Diagnostics®, Inc., a privately held global diagnostics company with a proprietary bionanochemistry platform; Chairman for Child Health Research Institute- d/b/a CureKids®, a global children's charity; a Partner for Endeavour Capital, an Asia/Pacific venture capital Firm in the life sciences, cleantech and information communication technologies (ICT). He was previously President & COO/CEO for EntreMed Pharmaceuticals (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing angiogenesis inhibitors for the treatment of cancer. Prior to EntreMed, Mr. Campbell served as Senior Director of Commercial Development for Celera Genomics (NASDAQ:CRA), where he built global genomic & proteomic businesses around the human genome project. Mr. Campbell has held General & Executive Management positions at Life Technologies, Inc. (NASDAQ: LIFE), IGEN, Inc., acquired by Roche (NASDAQ:IGEN), and Abbott Laboratories (NYSE: ABT) the global diversified healthcare company. Mr. Campbell was also a member of the Faculty for many years of the Carey Graduate School of Business at the Johns Hopkins University and lectured in the JHU Medical Institutes as part of a joint business/medicine program. Mr. Campbell is now a visiting professor/research fellow at universities in the USA, Europe and Asia.



During his career, Mr. Campbell has successfully developed and/or introduced more than 300 products and services in the areas of high-performance computing, medical software, e-commerce, pharmaceuticals, medical devices, clinical & industrial diagnostics, consumer healthcare products, research products, bioinformatics and nanotechnology. Mr. Campbell serves on several industry, government, non-profit and company boards and is a well-published author on a wide variety of subjects relating to the research, development and commercialization of science and technology.



Mr. Campbell earned his M.B.A. and M.A. from Webster University and his B.S. from Norwich University.